DK2370101T3 - Anvendelse af flt3-ligand til forstærkning af immunreaktioner ved rna-immunisering - Google Patents
Anvendelse af flt3-ligand til forstærkning af immunreaktioner ved rna-immuniseringInfo
- Publication number
- DK2370101T3 DK2370101T3 DK09796949.7T DK09796949T DK2370101T3 DK 2370101 T3 DK2370101 T3 DK 2370101T3 DK 09796949 T DK09796949 T DK 09796949T DK 2370101 T3 DK2370101 T3 DK 2370101T3
- Authority
- DK
- Denmark
- Prior art keywords
- immune reactions
- flt3 ligand
- amplify immune
- rna immunization
- immunization
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55516—Proteins; Peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Oncology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Communicable Diseases (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Virology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE102008061522A DE102008061522A1 (de) | 2008-12-10 | 2008-12-10 | Verwendung von Flt3-Ligand zur Verstärkung von Immunreaktionen bei RNA-Immunisierung |
PCT/EP2009/008811 WO2010066418A1 (de) | 2008-12-10 | 2009-12-09 | Verwendung von flt3-ligand zur verstärkung von immunreaktionen bei rna-immunisierung |
Publications (1)
Publication Number | Publication Date |
---|---|
DK2370101T3 true DK2370101T3 (da) | 2013-05-13 |
Family
ID=41720572
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK09796949.7T DK2370101T3 (da) | 2008-12-10 | 2009-12-09 | Anvendelse af flt3-ligand til forstærkning af immunreaktioner ved rna-immunisering |
Country Status (9)
Country | Link |
---|---|
US (1) | US9486519B2 (da) |
EP (1) | EP2370101B8 (da) |
JP (2) | JP5931443B2 (da) |
AU (1) | AU2009326524B2 (da) |
CA (1) | CA2747180C (da) |
DE (1) | DE102008061522A1 (da) |
DK (1) | DK2370101T3 (da) |
ES (1) | ES2407994T3 (da) |
WO (1) | WO2010066418A1 (da) |
Families Citing this family (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE10347710B4 (de) | 2003-10-14 | 2006-03-30 | Johannes-Gutenberg-Universität Mainz | Rekombinante Impfstoffe und deren Verwendung |
DE102005046490A1 (de) | 2005-09-28 | 2007-03-29 | Johannes-Gutenberg-Universität Mainz | Modifikationen von RNA, die zu einer erhöhten Transkriptstabilität und Translationseffizienz führen |
DE102008061522A1 (de) * | 2008-12-10 | 2010-06-17 | Biontech Ag | Verwendung von Flt3-Ligand zur Verstärkung von Immunreaktionen bei RNA-Immunisierung |
EP2281579A1 (en) | 2009-08-05 | 2011-02-09 | BioNTech AG | Vaccine composition comprising 5'-Cap modified RNA |
CA2786940C (en) | 2010-03-16 | 2019-09-24 | Biontech Ag | Tumor vaccination involving a humoral immune response, and proteins therefor including all or a portion of a hepatitis b virus core antigen protein and an epitope of claudin 18.2 |
EP2366709A1 (en) | 2010-03-16 | 2011-09-21 | BioNTech AG | Tumor vaccination involving a humoral immune response against self-proteins |
US9983194B2 (en) | 2011-04-01 | 2018-05-29 | New York University | Cancer diagnostics, therapeutics, and drug discovery associated with macropinocytosis |
CN103561765B (zh) | 2011-05-05 | 2015-06-17 | 沃尔斯塔特免疫疗法公司 | 补体因子b类似物及其用途 |
RS64230B1 (sr) | 2011-05-24 | 2023-06-30 | BioNTech SE | Individualizovane vakcine protiv kancera |
WO2013143555A1 (en) * | 2012-03-26 | 2013-10-03 | Biontech Ag | Rna formulation for immunotherapy |
EP3427723B1 (en) * | 2012-03-26 | 2020-08-05 | BioNTech RNA Pharmaceuticals GmbH | Rna formulation for immunotherapy |
EP3417874A1 (en) | 2012-11-28 | 2018-12-26 | BioNTech RNA Pharmaceuticals GmbH | Individualized vaccines for cancer |
WO2014180490A1 (en) | 2013-05-10 | 2014-11-13 | Biontech Ag | Predicting immunogenicity of t cell epitopes |
WO2016045732A1 (en) | 2014-09-25 | 2016-03-31 | Biontech Rna Pharmaceuticals Gmbh | Stable formulations of lipids and liposomes |
WO2016128060A1 (en) | 2015-02-12 | 2016-08-18 | Biontech Ag | Predicting t cell epitopes useful for vaccination |
WO2016138455A1 (en) | 2015-02-26 | 2016-09-01 | Sio2 Medical Products, Inc. | Cycloolefin polymer container with a scratch resistant and anti-static coating |
WO2017059902A1 (en) | 2015-10-07 | 2017-04-13 | Biontech Rna Pharmaceuticals Gmbh | 3' utr sequences for stabilization of rna |
WO2017162266A1 (en) | 2016-03-21 | 2017-09-28 | Biontech Rna Pharmaceuticals Gmbh | Rna replicon for versatile and efficient gene expression |
WO2017162265A1 (en) | 2016-03-21 | 2017-09-28 | Biontech Rna Pharmaceuticals Gmbh | Trans-replicating rna |
WO2018208856A1 (en) | 2017-05-08 | 2018-11-15 | Gritstone Oncology, Inc. | Alphavirus neoantigen vectors |
SG11202006400UA (en) | 2018-01-04 | 2020-08-28 | Iconic Therapeutics Inc | Anti-tissue factor antibodies, antibody-drug conjugates, and related methods |
US20200368268A1 (en) | 2018-01-08 | 2020-11-26 | Novartis Ag | Immune-enhancing rnas for combination with chimeric antigen receptor therapy |
US11246908B2 (en) | 2018-01-10 | 2022-02-15 | The Johns Hopkins University | Compositions comprising albumin-FMS-like tyrosine kinase 3 ligand fusion proteins and uses thereof |
BR112020026125A8 (pt) | 2018-03-15 | 2022-10-18 | Biontech Rna Pharmaceuticals Gmbh | Compostos oligonucleotídeos superiores ou 5'-cap- trinucleotídeo e seus usos na estabilização de rna, expressão de proteínas e em terapia |
CN112543768B (zh) | 2018-07-10 | 2024-05-03 | 里珍纳龙药品有限公司 | 修饰结合分子以最小化预先存在的相互作用 |
BR122024002387A2 (pt) | 2019-05-30 | 2024-03-12 | Gritstone Bio, Inc. | Vetores de adenovírus, composição farmacêutica, sequência de nucleotídeo isolada, célula isolada, vetor, kit, usos de um vetor, método para fabricar o vetor, métodos para produzir um vírus e vetor viral |
BR112021026376A2 (pt) | 2019-06-25 | 2022-05-10 | Gilead Sciences Inc | Proteínas de fusão flt3l-fc e métodos de uso |
AU2021286169A1 (en) | 2020-06-04 | 2023-01-19 | BioNTech SE | RNA replicon for versatile and efficient gene expression |
WO2022032196A2 (en) | 2020-08-06 | 2022-02-10 | Gritstone Bio, Inc. | Multiepitope vaccine cassettes |
BR112023002123A2 (pt) | 2020-08-07 | 2023-03-07 | Genentech Inc | Proteína de fusão fc, ácidos nucleicos isolados, método de produção da proteína de fusão fc, formulação farmacêutica, métodos para expandir o número de células dendríticas (dcs) em um indivíduo e para tratar um câncer, proteína fc sem efetora e anticorpo |
CA3201552A1 (en) | 2020-12-09 | 2022-06-16 | Thomas ZIEGENHALS | Rna manufacturing |
AU2022369342A1 (en) | 2021-10-18 | 2024-03-14 | BioNTech SE | Modified replicable rna and related compositions and their use |
AU2022372325A1 (en) | 2021-10-18 | 2024-05-02 | BioNTech SE | Methods for determining mutations for increasing modified replicable rna function and related compositions and their use |
WO2023213378A1 (en) | 2022-05-02 | 2023-11-09 | BioNTech SE | Replicon compositions and methods of using same for the treatment of diseases |
WO2024056856A1 (en) | 2022-09-15 | 2024-03-21 | BioNTech SE | Systems and compositions comprising trans-amplifying rna vectors with mirna |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4235871A (en) | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
US4501728A (en) | 1983-01-06 | 1985-02-26 | Technology Unlimited, Inc. | Masking of liposomes from RES recognition |
US5019369A (en) | 1984-10-22 | 1991-05-28 | Vestar, Inc. | Method of targeting tumors in humans |
US4837028A (en) | 1986-12-24 | 1989-06-06 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
US5554512A (en) | 1993-05-24 | 1996-09-10 | Immunex Corporation | Ligands for flt3 receptors |
US6291661B1 (en) | 1998-07-02 | 2001-09-18 | Immunex Corporation | flt3-L mutants and method of use |
US7005131B1 (en) * | 1999-08-13 | 2006-02-28 | The Rockefeller University | Protective antigen of Epstein Barr Virus |
EP1363660A4 (en) | 2001-02-01 | 2006-06-21 | Univ Johns Hopkins | HIGHER MOLECULAR VACCINE BASED ON AUTOMPLICATIVE RNA, SUICIDE DNA OR UNDNA DNA VECTOR, WHICH LINKS ANTIGEN WITH A POLYPEPTIDE WHICH PROMOTES THE PRESENTATION OF THE ANTIGEN |
WO2005052119A2 (en) | 2003-11-19 | 2005-06-09 | Beth Israel Deaconess Medical Center | Adjuvants of immune response |
DE102005046490A1 (de) | 2005-09-28 | 2007-03-29 | Johannes-Gutenberg-Universität Mainz | Modifikationen von RNA, die zu einer erhöhten Transkriptstabilität und Translationseffizienz führen |
JP5755839B2 (ja) * | 2007-02-15 | 2015-07-29 | マンカインド コーポレイション | T細胞応答の増強方法 |
DE102008061522A1 (de) * | 2008-12-10 | 2010-06-17 | Biontech Ag | Verwendung von Flt3-Ligand zur Verstärkung von Immunreaktionen bei RNA-Immunisierung |
-
2008
- 2008-12-10 DE DE102008061522A patent/DE102008061522A1/de not_active Withdrawn
-
2009
- 2009-12-09 DK DK09796949.7T patent/DK2370101T3/da active
- 2009-12-09 JP JP2011539947A patent/JP5931443B2/ja active Active
- 2009-12-09 WO PCT/EP2009/008811 patent/WO2010066418A1/de active Application Filing
- 2009-12-09 AU AU2009326524A patent/AU2009326524B2/en active Active
- 2009-12-09 ES ES09796949T patent/ES2407994T3/es active Active
- 2009-12-09 EP EP09796949.7A patent/EP2370101B8/de active Active
- 2009-12-09 CA CA2747180A patent/CA2747180C/en active Active
- 2009-12-09 US US13/139,034 patent/US9486519B2/en active Active
-
2014
- 2014-12-11 JP JP2014250521A patent/JP2015083585A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
CA2747180A1 (en) | 2010-06-17 |
DE102008061522A1 (de) | 2010-06-17 |
JP5931443B2 (ja) | 2016-06-08 |
ES2407994T3 (es) | 2013-06-17 |
AU2009326524B2 (en) | 2012-06-07 |
AU2009326524A8 (en) | 2011-09-08 |
JP2012511528A (ja) | 2012-05-24 |
EP2370101B8 (de) | 2013-05-01 |
AU2009326524A1 (en) | 2011-07-21 |
JP2015083585A (ja) | 2015-04-30 |
EP2370101B1 (de) | 2013-03-27 |
WO2010066418A8 (de) | 2010-08-12 |
CA2747180C (en) | 2015-02-03 |
EP2370101A1 (de) | 2011-10-05 |
US9486519B2 (en) | 2016-11-08 |
US20110311584A1 (en) | 2011-12-22 |
WO2010066418A1 (de) | 2010-06-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK2370101T3 (da) | Anvendelse af flt3-ligand til forstærkning af immunreaktioner ved rna-immunisering | |
DK2611461T3 (da) | Pegylerede liposomer til afgivelse af RNA, der koder immunogen | |
DK3251503T3 (da) | Genetisk modificering af mus til fremstilling af kimære antistoffer | |
DK2885408T3 (da) | Digital til biologisk konverter | |
DK2818183T3 (da) | Antigen-bindende molekyle til at fremme forsvinden af antigen ved hjælp af Fc RIIB | |
DK2285779T3 (da) | Fremgangsmåde til fremstilling af arylcarboxamider | |
DK2539450T3 (da) | Fremgangsmåde til fremstilling af nukleinsyrebiblioteker | |
DK2879718T3 (da) | Proces til fremstilling af kulhydratkonjugerede RNA-stoffer | |
DK2699698T4 (da) | Oscillerende amplifikations-reaktion for nukleinsyrer | |
DK2449057T3 (da) | Fremgangsmåde til omdannelse af lignocellulosematerialer til anvendelige kemikalier | |
DK3109326T3 (da) | Sammensætning og fremgangsmåde til nukleinsyresyntese og amplifikation under anvendelse af rt | |
DK2346994T3 (da) | Knock-in-mus til fremstilling af kimære antistoffer | |
IL208313A0 (en) | Neutralizing molecules to viral antigens | |
DK2076540T3 (da) | Hidtil ukendte anti-cd38-antistoffer til behandling af cancer | |
DK2553113T3 (da) | FREMGANGSMÅDE TIL FREMSTILLING AF L-ORNITHIN UNDER ANVENDELSE AF LysE-OVEREKSPRIMERENDE BAKTERIER | |
EP2254597A4 (en) | TREATMENT PROCEDURE WITH ANTI-MIF ANTIBODIES | |
DK2662352T3 (da) | Fremgangsmåde til fremstilling af phenylacetamidforbindelse | |
DK3243526T3 (da) | Levering af rna til at udløse flere immunsignalveje | |
DK3329775T3 (da) | Fremgangsmåder til syntese af diarylthiohydantoin- og diarylhydantoinforbindelser | |
DK2483399T3 (da) | Hydrolyse af mannose-1-phospho-6-mannose-binding til phospho-6-mannose | |
DK2496562T3 (da) | Fremgangsmåde til fremstilling af calcobutrol | |
DK2375786T3 (da) | System til programmering af specielle funktionsknapper til anvendelse tilhørehjælpsanordninger | |
DK2399606T3 (da) | Fremgangsmåde til fremstilling af varmebestandig oxygenbærerholdig farmaceutisk sammensætning | |
DK2610346T3 (da) | Forbedret præ-udblødningsproces til biomasseomdannelse | |
DK2430196T3 (da) | Fremgangsmåde til fremstilling af alkoholer |